Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-09
2011-08-09
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S009400, C514S021300, C514S021400, C514S021500
Reexamination Certificate
active
07994116
ABSTRACT:
The present invention relates to a method for prevention or reduction of scar tissue and/or adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.
REFERENCES:
patent: 5196430 (1993-03-01), Mandell et al.
patent: 5994376 (1999-11-01), Freyne et al.
patent: 6348602 (2002-02-01), Fowler et al.
patent: 2002/0072596 (2002-06-01), Ruben et al.
patent: 08143468 (1996-06-01), None
patent: WO 89/05145 (1989-06-01), None
patent: WO 98/06715 (1998-02-01), None
patent: WO 01/57018 (2001-08-01), None
patent: WO 01/58469 (2001-08-01), None
Black L.E. “Pharmacology review of infliximab BLA”—May 21, 1998-found at internet address: http://www.fda.gov/cder/biologics/review/inflcen082498r4.pdf.
Rekdal et al., “Construction and Synthesis of Lactoferricin Derivatives with Enhanced Antibacterial Activity”, Journal of Peptide Science, 1999, vol. 5, pp. 32-45.
STN International, File ZCAPLUS, Accession No. 2002:199887, Document No, 136:323691, Kaser, Arthur et al., “Infliximab in Severe Steroid-Refractoty Ulcerative Colitis: A Pilot Study”, & Wiener Klinische Wochenschrift (2001), 113(23-24), 930-933.
STN International, File MEDLINE, Accession No. 2000046083, Document No. 20046083, Heller T. et al., “Treatment of Severe Esophageal Crohn's Disease With Infliximab”, & Inflammatory Bowel Diseases, (Nov. 1999) 5 (4) 279-82.
STN International, File MEDLINE, Accession No. 2001011857, Document No. 20409486, Jojic N., “[Pharmacotherapy of Inflammatory Bowel Disease].Farmakoterapija Inflamatornih Bolesti Creva”, & ACTA Chirurgica Jugoslavica, (2000) 47 (1-2) 51-5.
STN International, File MEDLINE, Accession No. 2001419273, Document No. 21360250, Blam M,E., “Integrating Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Current and Future Perspectives”, American Journal of Gastroenterology, (Jul. 2001) 96 (7) 1977-97.
STN International, File MEDLINE, Accession No. 2001553668, Document No. 21486185, Travis S.P, et al., “Treatment of Intestinal Behcet's Syndrome With Chimeric Tumour Necrosis Factor Alpha Antibody”, & GUT, (Nov. 2001) 49 (5) 725-8.
Elin Nilsson et al., “A Novel Polypeptide Derived From Human Lactoferrin in Sodium Hyaluronate Prevents Postsurgical Adhesion Formation in the Rat,” 250(6) Annals of Surgery 1021-1028 (Dec. 2009).
M.-L. Ivarsson et al. “Tissue markers as predictors of postoperative adhesions,” 85 British Journal of Surgery 1549-1554 (1998).
Buchanan & Ingersoll & Rooney PC
Landsman Robert
PharmaSurgics in Sweden AB
LandOfFree
Methods for reduction of adhesion formation using cytokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for reduction of adhesion formation using cytokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reduction of adhesion formation using cytokine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2778517